Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke.
Sphingomyelin synthase (SGMS) is responsible for the production of sphingomyelin (SGM), the second most abundant phospholipid in mammalian plasma, from ceramide, a major sphingolipid. Knowledge of the effects of cigarette smoke on sphingomyelin production is limited. Here, we examine the effect of chronic cigarette smoke on SGMS activity and evaluate how the deficiency of Sgms2, one of the two isoforms of mammalian SGMS, impacts pulmonary function. Sgms2 knockout and wild type control mice were exposed to cigarette smoke for 6 months and pulmonary function testing was performed. SGMS2-dependent signaling was investigated in these mice and in human macrophages derived from monocytes (MDM) of nonsmokers and human bronchial epithelial (HBE) cells isolated from healthy nonsmokers and COPD subjects. Chronic cigarette smoke reduces SGMS activity and Sgms2 gene expression in mouse lungs. Sgms2-deficient mice exhibited enhanced airway and tissue resistance following chronic cigarette smoke exposure, but have similar levels of emphysema compared to smoke-exposed wild type mice. Sgms2-/- mice had greater AKT phosphorylation, peribronchial collagen deposition and protease activity in their lungs following smoke inhalation. Similarly, we identified reduced SGMS2 expression and enhanced phosphorylation of AKT and protease production in HBE cells isolated from COPD subjects. Selective inhibition of AKT activity or overexpression of SGMS2 reduced the production of several MMPs in HBE cells and MDM cells. Our study demonstrates that smoke-regulated Sgms2 gene expression influences key COPD features in mice including airway resistance, AKT signaling and protease production.